Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDA triple therapy in Wuchereria bancrofti infection
NCT02845713Phase 1Completed
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivermectin, diethylcarbamazine and albendazole in bancroftian lymphatic filariasis (2 arms), sponsored by University Hospitals Cleveland Medical Center. Primary endpoint: Drug Levels at 12 hours. Started Apr 2016; status: completed.
02
Drugs
ivermectindiethylcarbamazinealbendazole
03
Conditions
bancroftian lymphatic filariasis
Beyond the preview
Go deeper on NCT02845713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02845713.